About
Epicrispr Biotechnologies is a clinical-stage biotechnology company pioneering gene-modulating therapies. They are focused on developing a new class of programmable epigenetic medicines designed to durably regulate gene expression without permanently altering the underlying DNA sequence. Their lead program, EPI-321, is in clinical trials for Facioscapulohumeral Muscular Dystrophy (FSHD).
Key facts
At-a-glance profile data
- Website
- epicrispr.com
- Headquarters
- South San Francisco, United States
- Founded
- 2020
- Employees
- 51
- Total funding
- $90M (Series C)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 10 Aug 2026 | Series C | $90M | - |
Tech stack
Detected on epicrispr.com, last scanned 15 Sept 2026. Run your own scan
- Frontend
- jQuery, Tailwind CSS, Bootstrap
- Analytics
- Google Analytics 4
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Google Workspace
- Email marketing
- Mailchimp
Frequently asked
Is Epicrispr Biotechnologies trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Epicrispr Biotechnologies is 52 out of 100, based on site security posture and privacy practices.
How much funding has Epicrispr Biotechnologies raised?
Epicrispr Biotechnologies has raised a total of $90M in funding. The most recent round on record is Series C.
How many employees does Epicrispr Biotechnologies have?
Epicrispr Biotechnologies has approximately 51 people on record.